spinal muscular atrophy

From no drugs to 3: Patients with spinal muscular atrophy now face hard choices
From no drugs to 3: Patients with spinal muscular atrophy now face hard choices
BioPharma Dive
SMA
spinal muscular atrophy
Novartis
Zolgensma
Spinraza
Roche
Evrysdi
Flag link:
Biogen to Run Phase IV SMA Trial: “I Want to Optimize Their Life.”
Biogen to Run Phase IV SMA Trial: “I Want to Optimize Their Life.”
BioSpace
Biogen
SMA
spinal muscular atrophy
Spinraza
clinical trials
Flag link:
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
Xconomy
Roche
risdiplam
SMA
spinal muscular atrophy
FDA
Flag link:
Biogen to launch Phase IV study of spinal muscular atrophy drug in post-gene therapy patients
Biogen to launch Phase IV study of spinal muscular atrophy drug in post-gene therapy patients
MedCity News
Biogen
clinical trials
Spinraza
Novartis
Zolgensma
SMA
spinal muscular atrophy
Flag link:
New Zolgensma 'inflection point' is here as Novartis snags EU nod for SMA gene therapy
New Zolgensma 'inflection point' is here as Novartis snags EU nod for SMA gene therapy
Fierce Pharma
Novartis
Zolgensma
SMA
spinal muscular atrophy
gene therapy
Europe
Flag link:
Roche shares SMA data ahead of scrap with Biogen, Novartis
Roche shares SMA data ahead of scrap with Biogen, Novartis
Fierce Biotech
Roche
Biogen
Novartis
SMA
spinal muscular atrophy
risdiplam
clinical trials
Flag link:
With supply tight, Novartis readies gene therapy plant for production
With supply tight, Novartis readies gene therapy plant for production
BioPharma Dive
Novartis
Zolgensma
spinal muscular atrophy
drug manufacturing
Flag link:
Novartis' latest Zolgensma data bode well for use in older patients
Novartis' latest Zolgensma data bode well for use in older patients
Fierce Pharma
Novartis
Zolgensma
SMA
FDA
spinal muscular atrophy
Flag link:
Novartis, shadowed by data scandal, renews case for Zolgensma
Novartis, shadowed by data scandal, renews case for Zolgensma
Biopharma Dive
Novartis
Zolgensma
SMA
spinal muscular atrophy
Flag link:
Biogen ramps up its SMA rivalry with Novartis with new Spinraza trial
Biogen ramps up its SMA rivalry with Novartis with new Spinraza trial
Fierce Pharma
Biogen
clinical trials
Spinraza
SMA
spinal muscular atrophy
Novartis
Flag link:
Novartis used manipulated data in winning Zolgensma approval, FDA says
Novartis used manipulated data in winning Zolgensma approval, FDA says
Biopharma Dive
Novartis
FDA
Zolgensma
data
spinal muscular atrophy
gene therapy
AveXis
Flag link:
Roche, PTC post latest SMA data from their attempt to rival Spinraza, Zolgensma
Roche, PTC post latest SMA data from their attempt to rival Spinraza, Zolgensma
Fierce Biotech
Roche
PTC Therapeutics
spinal muscular atrophy
risdiplam
Novartis
Zolgensma
Biogen
Spinraza
Flag link:
New Zolgensma data suggest comparable efficacy to Spinraza — analysts
New Zolgensma data suggest comparable efficacy to Spinraza — analysts
Endpoints
Novartis
FDA
spinal muscular atrophy
Zolgensma
AveXis
Biogen
Spinraza
Flag link:
Novartis makes final Zolgensma pitch before FDA decision
Novartis makes final Zolgensma pitch before FDA decision
BioPharma Dive
Novartis
gene therapy
Zolgensma
FDA
spinal muscular atrophy
Flag link:
SMA Moment: Will Gene Therapy Shift Treatment, Costs of Muscle Disease?
SMA Moment: Will Gene Therapy Shift Treatment, Costs of Muscle Disease?
Xconomy
gene therapy
SMA
spinal muscular atrophy
Novartis
Zolgensma
Flag link:
Novartis mulling $1.5 mln-$5 mln price range for SMA gene therapy
Novartis mulling $1.5 mln-$5 mln price range for SMA gene therapy
Yahoo/Reuters
Novartis
Zolgensma
gene therapy
drug pricing
spinal muscular atrophy
Flag link:
Ionis slides after AveXis reports SMA data for Zolgensma
Ionis slides after AveXis reports SMA data for Zolgensma
BioCentury
Ionis Pharmaceuticals
AveXis
Zolgensma
lcinical trials
spinal muscular atrophy
Flag link:
With FDA decision near, Novartis bolsters SMA gene therapy case
With FDA decision near, Novartis bolsters SMA gene therapy case
Biopharma Dive
Novartis
FDA
Zolgensma
spinal muscular atrophy
Flag link:
Novartis' SMA gene therapy would not be cost-effective if priced over $1.5M: ICER
Novartis' SMA gene therapy would not be cost-effective if priced over $1.5M: ICER
Fierce Pharma
Novartis
ICER
drug pricing
Zolgensma
gene therapy
spinal muscular atrophy
Flag link:
ICER's life year calculation gives Novartis wider pricing ballpark for SMA therapy
ICER's life year calculation gives Novartis wider pricing ballpark for SMA therapy
BioCentury
Novartis
Zolgensma
AVXS-101
spinal muscular atrophy
ICER
Flag link:

Pages